Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-08-31

Study Completion Date

2014-06-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized phase II trial studies how well giving spironolactone works in preventing rash in patients with cancer that has spread to other places in the body and are receiving panitumumab and cetuximab. Spironolactone may prevent endothelial growth factor receptor (EGFR) inhibitor-induced skin rash.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Acitretin in Preventing Skin Cancer in Patients at High Risk for Skin Cancer

NCT00644384

Non-melanomatous Skin Cancer

COMPLETED NA

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

NCT07042295

Locally Recurrent Skin Squamous Cell Carcinoma Metastatic Skin Squamous Cell Carcinoma

NOT_YET_RECRUITING PHASE2

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors

NCT04802876

MSI-H Colorectal Cancer Melanoma Anal Carcinoma +28 more

ACTIVE_NOT_RECRUITING PHASE2

Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

NCT06762808

Squamous Cell Carcinoma

WITHDRAWN PHASE2

Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC

NCT05085496

Locally Advanced Skin Squamous Cell Carcinoma Resectable Skin Squamous Cell Carcinoma Unresectable Skin Squamous Cell Carcinoma

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To determine feasibility of the administration of topical spironolactone versus placebo in this patient population. (Study I) II. To further explore the efficacy of the topical spironolactone to prevent/attenuate rash from EGFR inhibitors. (Study II)

SECONDARY OBJECTIVES:

I. To explore efficacy of the spironolactone versus placebo. (Study I) II. To describe the efficacy of a Modified Preemptive Therapy Regimen intervention. (Study II) III. To explore the adverse event profile of spironolactone and the Modified Preemptive Therapy Regimen intervention. (Study II) IV. To explore patient reported outcomes of patients using spironolactone and a Modified Preemptive Therapy Regimen intervention. (Study II) V. To explore long term (8 week) effect of the 4 week treatment of spironolactone and a Modified Preemptive Therapy Regimen intervention on EFGR induced rash. (Study II)

OUTLINE:

STUDY I: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients apply spironolactone topically to face twice daily (BID) for 4 weeks.

ARM II: Patients apply placebo topically to face BID for 4 weeks.

STUDY II: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients apply spironolactone topically to face and body BID for 4 weeks

ARM II: Patients undergo modified preemptive therapy regimen consisting of skin moisturizer topically BID, sunscreen topically before going outside, hydrocortisone topically once daily (QD), and doxycycline orally (PO) BID for 4 weeks.

After completion of study, patients are followed up for 4 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Malignant Neoplasm Dermatologic Complication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Participants

Intervention Type DRUG

Given topically

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Doxycycline Monohydrate placebo therapy PLCB sham therapy 17-Hydroxy-7alpha-mercapto-3-oxo-17alpha-pregn-4-ene-21-carboxylic Acid, gamma Lactone, Acetate Aldactone SC 9420 SPL Sunblock Aeroseb-HC Barseb HC Barseb-HC Cetacort Cort-Dome Cortef Cortenema Cortifan Cortisol Cortispray Cortril Dermacort Domolene Eldecort Hautosone Heb-Cort hydrocortisone Hydrocortone Hytone Komed-HC Nutracort Proctocort Rectoid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Scheduled to start panitumumab or cetuximab; patients must not have been on the EGFR agent prior to randomization
* Ability to reliably apply topical spironolactone/placebo twice a day to the face
* Ability to complete questionnaire(s) by themselves or with assistance
* For study 2 only, patients must be willing to avoid sun exposure for one month from registration
* Creatinine =\< 1.5 x upper limit of normal (UNL)
* For Study 2 only, ability to apply topical creams to the entire face and body

Exclusion Criteria

* Prior allergic reaction or severe intolerance to spironolactone
* Any rash at the time of randomization
* Cutaneous metastases
* Any other disorder that may predispose to hyperkalemia in the opinion of the treating oncologist
* Use of topical corticosteroids at the time of study or their anticipated use in the next 8 weeks; (it is acknowledged that patients may be starting these agents pre-emptively as part of this protocol)
* For study 2 only, previous intolerance of sunscreen or any of the other components of the Modified Preemptive Therapy Regimen (a moisturizer or oral doxycycline)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No